Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.» Read More
Basically, the patient makes his own drug, says Stephane Bancel, Moderna Therapeutics CEO explaining how his company is revolutionizing mRNA technology.
CNBC's Julia Boorstin takes a look at how Moderna Therapeutics is disrupting the biotech world.
CNBC's Jim Cramer gives his call on the "only really legitimate marijuana stock" in the market and a food company.
US Agriculture Secretary is confident an approved vaccine would help fight a deadly virus that has killed millions of pigs.
Valeant said it plans to launch an exchange offer to Allergan shareholders this week, soliciting proxies to call for a meeting to discuss its offer.
Shire has hired investment bank Citi as an adviser following a wave of deals in the healthcare sector.
Medtronic's $43 billion Covidien deal may signal future medical-device company mergers.
Medtronic is buying Covidien in a $42.9 billion agreement that could increase concerns about the rush of U.S. companies striking deals to cut their tax bills.
Many of the world's biggest drugmakers will gather starting Friday in San Francisco for the American Diabetes Association's annual meeting. Here's what investors need to know.
Orexigen Therapeutics shares fell 15 percent after the FDA delayed its decision on the drug pending post-marketing safety monitoring requirements.
Orexigen Therapeutics said the FDA delayed a decision on its obesity drug by three months, sending the company's shares down about 19 percent.
Baupost Group appears to have made a nearly $1 billion off of Merck's deal to buy Idenix.
Achillion's been a takeover target for years. But Merck's acquisition of Idenix may mean Achillion's time has come.
Allergan's board of directors announced on Tuesday that it has unanimously rejected a revised, unsolicited buyout offer from Valeant Pharmaceuticals.
Analysts say there's more to Merck's interest in Idenix than its drug portfolio: intellectual property. And that's why Gilead's shares are lower.
An FDA decision on Orexigen's obesity drug, Contrave, is expected Wednesday, and analysts say its late arrival on market may help.
Drug giant Merck said it would purchase Idenix Pharmaceuticals for $3.85 billion, a deal already approved by both companies' board of directors.
This is the perfect environment for investing in stocks, Fred Alger Management's Daniel Chung said. Here are two names he likes.
A small agricultural biotech company in Ames, Iowa, may have found a treatment for a disease that's wiping out pigs.
Clovis shares fell to a 52-week low Tuesday on concerns its cancer drug won't be able to compete with rival AstraZeneca.
Get the best of CNBC in your inbox